Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Abiomed Inc Maintains FY 2014 Revenue Guidance


Wednesday, 6 Nov 2013 07:00am EST 

Abiomed Inc announced that it is maintaining its fiscal 2014 revenue guidance in the range of $180 million to $185 million, with worldwide Impella revenue forecasted to increase by approximately 20%. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report revenue of $181 million for fiscal 2014. 

Company Quote

23.76
0.21 +0.89%
2:07pm EDT